keyword
MENU ▼
Read by QxMD icon Read
search

breast chemotherapy

keyword
https://www.readbyqxmd.com/read/28346258/management-of-metastatic-breast-carcinoma-of-iris-with-intraocular-bevacizumab-injections
#1
G Ece Akinci, Ahmet M Hondur, Tongalp H Tezel
PURPOSE: To describe intraocular use of bevacizumab for a metastatic breast carcinoma of the iris resistant to advanced systemic chemotherapy protocols, for which conventional treatment would be local radiotherapy or brachytherapy. METHODS: Case report. RESULTS: A 65-year-old woman, who was previously diagnosed with breast carcinoma and treated with radical mastectomy coupled with radiotherapy and chemotherapy, presented with an iris mass in her left eye...
March 24, 2017: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/28345838/ercc1-expression-in-metastatic-triple-negative-breast-cancer-patients-treated-with-platinum-based-chemotherapy
#2
Mohamed Ali EL Baiomy, Wagdi F El Kashef
Background: Possible targeted therapies for metastatic triple negative breast cancer (TNBC) include cytotoxic chemotherapy that causes interstrand breaks (platinum-based drugs). The excision repair cross-complementation 1 (ERCC1) enzyme plays an essential role in the nucleotide excision repair pathway, removing platinum-induced DNA adducts and contributing to cisplatin resistance. Detecting ERCC1 overexpression is important in considering treatment options for metastatic TNBC, including individualized approaches to therapy, and may facilitate improved responses or reduction of unnecessary toxicity...
February 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28345737/-meningeal-carcinomatosis-in-breast-cancer-from-diagnosis-to-treatment
#3
REVIEW
C Elm'hadi, Z Es Sbai, M Reda Khmamouche, M Toreis, R Tanz, H Errihani, M Ichou
The appearance of meningeal carcinomatosis in breast cancer is an event that is being reported increasingly more frequently in the literature. It seems to be related with the lengthening of the patients' lives, improved sensitivity to diagnostic imaging and impermeability of the blood-brain barrier to the chemotherapeutic agents. It is an evolutionary form that affirms the metastatic invasion of the subarachnoidal space and is correlated with limited survival. Its diagnosis is difficult, due to the lack of specificity of the clinical signs dominated by headaches, cognitive disorders and possible signs and symptoms of progressive focal lesions...
April 1, 2017: Revista de Neurologia
https://www.readbyqxmd.com/read/28345629/wt1-expression-in-breast-cancer-disrupts-the-epithelial-mesenchymal-balance-of-tumour-cells-and-correlates-with-the-metabolic-response-to-docetaxel
#4
Mara Artibani, Andrew H Sims, Joan Slight, Stuart Aitken, Anna Thornburn, Morwenna Muir, Valerie G Brunton, Jorge Del-Pozo, Linda R Morrison, Elad Katz, Nicholas D Hastie, Peter Hohenstein
WT1 is a transcription factor which regulates the epithelial-mesenchymal balance during embryonic development and, if mutated, can lead to the formation of Wilms' tumour, the most common paediatric kidney cancer. Its expression has also been reported in several adult tumour types, including breast cancer, and usually correlates with poor outcome. However, published data is inconsistent and the role of WT1 in this malignancy remains unclear. Here we provide a complete study of WT1 expression across different breast cancer subtypes as well as isoform specific expression analysis...
March 27, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28344858/nab-paclitaxel-for-the-treatment-of-breast-cancer-an-update-across-treatment-settings
#5
REVIEW
Adam Brufsky
PURPOSE: The purpose of this systematic review is to discuss recent studies and ongoing trials of nab-paclitaxel in breast cancer and to examine the potential role of nab-paclitaxel as a backbone for immuno-oncology therapies. METHODS: PubMed and selected congress proceedings were searched for studies of nab-paclitaxel in breast cancer published between 2013 and 2015. All phase II and III clinical trials, retrospective analyses, and institutional studies were included...
2017: Experimental Hematology & Oncology
https://www.readbyqxmd.com/read/28341972/a-prospective-study-of-aromatase-inhibitor-therapy-initiation-and-self-reported-side-effects
#6
Lisa Gallicchio, Carla Calhoun, Kathy Helzlsouer
PURPOSE: The objective of this study was to examine the associations between aromatase inhibitors (AIs) and side effects less frequently reported in the literature, including difficulty concentrating, forgetfulness, hair loss, and numbness in the extremities. METHODS: Data were analyzed from a cohort of 146 breast cancer patients initiating AI therapy and followed for 1 year and a cohort of 144 postmenopausal women without a history of cancer followed for 6 months...
March 24, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28341762/a-prospective-observational-study-on-effect-of-short-term-periodic-steroid-premedication-on-bone-metabolism-in-gastrointestinal-cancer-espresso-01
#7
Michio Nakamura, Atsushi Ishiguro, Tetsuhito Muranaka, Hiraku Fukushima, Satoshi Yuki, Kota Ono, Taichi Murai, Chika Matsuda, Ayane Oba, Kazufumi Itaya, Takayuki Sone, Masataka Yagisawa, Yuta Koike, Ayana Endo, Yoko Tsukuda, Yuji Ono, Takahiko Kudo, Atsushi Nagasaka, Shuji Nishikawa, Yoshito Komatsu
BACKGROUND: A multicenter prospective observational study evaluated the effect of gastrointestinal cancer chemotherapy with short-term periodic steroid premedication on bone metabolism. PATIENTS AND METHODS: Seventy-four patients undergoing chemotherapy for gastrointestinal cancer were studied. The primary endpoints were changes in bone mineral densities (BMDs) and metabolic bone turnover 16 weeks after initiation of chemotherapy. BMDs, measured by dual-energy x-ray absorptiometry, and serum cross-linked N-telopeptides of type I collagen (sNTX), and bone alkaline phosphatase (sBAP) were assessed for evaluation of bone resorption and formation, respectively...
March 24, 2017: Oncologist
https://www.readbyqxmd.com/read/28341761/cardiac-safety-of-dual-anti-her2-therapy-in-the-neoadjuvant-setting-for-treatment-of-her2-positive-breast-cancer
#8
Anthony F Yu, Jasmeet C Singh, Rui Wang, Jennifer E Liu, Anne Eaton, Kevin C Oeffinger, Richard M Steingart, Clifford A Hudis, Chau T Dang
BACKGROUND: Trastuzumab and pertuzumab are approved for the neoadjuvant treatment of human epidermal growth receptor 2 (HER2)-positive breast cancer, but cardiac safety data is limited. We report the cardiac safety of dose-dense doxorubicin and cyclophosphamide (AC) followed by paclitaxel, trastuzumab, and pertuzumab (THP) in the neoadjuvant setting followed by adjuvant trastuzumab-based therapy. METHODS: Fifty-seven patients treated with neoadjuvant dose-dense AC-THP followed by adjuvant trastuzumab-based therapy between September 1, 2013, and March 1, 2015, were identified...
March 24, 2017: Oncologist
https://www.readbyqxmd.com/read/28341751/low-recombination-proficiency-score-rps-predicts-heightened-sensitivity-to-dna-damaging-chemotherapy-in-breast-cancer
#9
Sean Pitroda, Riyue Bao, Jorge Andrade, Ralph R Weichselbaum, Philip P Connell
PURPOSE: Molecular-based cancer tests have been developed to augment the standard clinical and pathologic features used to tailor treatments to individual breast cancer patients. Homologous recombination (HR) repairs double-stranded DNA breaks and promotes tolerance to lesions that disrupt DNA replication. Recombination Proficiency Score (RPS) quantifies HR efficiency based on the expression of four genes involved in DNA damage repair. We hypothesized low RPS values can identify HR-deficient breast cancers most sensitive to DNA-damaging chemotherapy...
March 24, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28340615/glucocorticoids-induce-production-of-reactive-oxygen-species-reactive-nitrogen-species-and-dna-damage-through-an-inos-mediated-pathway-in-breast-cancer
#10
Renée L Flaherty, Matthew Owen, Aidan Fagan-Murphy, Haya Intabli, David Healy, Anika Patel, Marcus C Allen, Bhavik A Patel, Melanie S Flint
BACKGROUND: Psychological stress increases the circulating levels of the stress hormones cortisol and norepinephrine (NE). Chronic exposure to elevated stress hormones has been linked to a reduced response to chemotherapy through induction of DNA damage. We hypothesize that stress hormone signalling may induce DNA damage through the production of reactive oxygen species (ROS)/reactive nitrogen species (RNS) and interference in DNA repair processes, promoting tumourigenesis. METHODS: Breast cancer cell lines were incubated with physiological levels of cortisol and NE in the presence and absence of receptor antagonists and inducible nitric oxide synthase (iNOS) inhibitors and DNA damage measured using phosphorylated γ-H2AX...
March 24, 2017: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/28338617/egfr-family-members-regulation-of-autophagy-is-at-a-crossroads-of-cell-survival-and-death-in-cancer
#11
REVIEW
Elizabeth Henson, Yongqiang Chen, Spencer Gibson
The epidermal growth factor receptor (EGFR) signaling pathways are altered in many cancers contributing to increased cell survival. These alterations are caused mainly through increased expression or mutation of EGFR family members EGFR, ErbB2, ErbB3, and ErbB4. These receptors have been successfully targeted for cancer therapy. Specifically, a monoclonal antibody against ErbB2, trastuzumab, and a tyrosine kinase inhibitor against EGFR, gefitinib, have improved the survival of breast and lung cancer patients...
March 24, 2017: Cancers
https://www.readbyqxmd.com/read/28337968/crispr-cas9-mutagenesis-invalidates-a-putative-cancer-dependency-targeted-in-on-going-clinical-trials
#12
Ann Lin, Christopher J Giuliano, Nicole M Sayles, Jason M Sheltzer
The Maternal Embryonic Leucine Zipper Kinase (MELK) has been reported to be a genetic dependency in several cancer types. MELK RNAi and small-molecule inhibitors of MELK block the proliferation of various cancer cell lines, and MELK knockdown has been described as particularly effective against the highly-aggressive basal/triple-negative subtype of breast cancer. Based on these preclinical results, the MELK inhibitor OTS167 is currently being tested as a novel chemotherapy agent in several clinical trials. Here, we report that mutagenizing MELK with CRISPR/Cas9 has no effect on the fitness of basal breast cancer cell lines or cell lines from six other cancer types...
March 24, 2017: ELife
https://www.readbyqxmd.com/read/28337954/clinical-value-of-capecitabine-based-combination-adjuvant-chemotherapy-in-early-breast-cancer-a-meta-analysis-of-randomized-controlled-trials
#13
Guanling Chen, Zhaoze Guo, Minfeng Liu, Guangyu Yao, Jianyu Dong, Jingyun Guo, Changsheng Ye
Capecitabine has consistently demonstrated high efficacy and acceptable tolerability in salvage chemotherapy for advanced breast cancer. However, there remains no consensus on its role in adjuvant chemotherapy for early breast cancer (EBC). To estimate the value of capecitabine-based combination adjuvant treatment in EBC, eight randomized controlled trials with 14,072 participants were analyzed. The efficacy and safety outcomes included disease-free survival (DFS), overall survival (OS), relapse, breast cancer-specific survival (BCSS), and grade 3-5 adverse events...
March 23, 2017: Oncology Research
https://www.readbyqxmd.com/read/28337663/outcomes-of-fulvestrant-therapy-among-japanese-women-with-advanced-breast-cancer-a-retrospective-multicenter-cohort-study-jbcrg-c06-safari
#14
H Kawaguchi, N Masuda, T Nakayama, K Aogi, K Anan, Y Ito, S Ohtani, N Sato, S Saji, E Tokunaga, S Nakamura, Y Hasegawa, M Hattori, T Fujisawa, S Morita, M Yamaguchi, T Yamashita, Y Yamamoto, S Ohno, M Toi
PURPOSE: This retrospective study evaluated the effect of clinical background and treatment line on time to treatment failure (TTF) in advanced/metastatic breast cancer (AMBC) patients receiving F500 in Japan (UMIN 000015168). METHODS: Patients who commenced F500 treatment were registered at 16 sites in Japan. Correlations between baseline clinicopathological factors, treatment line, and TTF were investigated by Kaplan-Meier analysis. TTF data were analyzed using univariate analysis and multivariate analysis with a Cox proportional hazards model...
March 23, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28336457/synergistic-inhibition-of-migration-and-invasion-of-breast-cancer-cells-by-dual-docetaxel-quercetin-loaded-nanoparticles-via-akt-mmp-9-pathway
#15
Jing Li, Jun Zhang, Yiyue Wang, Xiao Liang, Zaitongguli Wusiman, Yunzhi Yin, Qi Shen
Metastasis impedes the successful chemotherapy for breast cancer. In this study, an Akt inhibitor (quercetin, Qu) was co-delivered with a chemotherapeutic agent (docetaxel, DTX) by using hyaluronic acid (HA)-modified nanoparticles (NPs) as vectors to block metastasis. Dual DTX/Qu-loaded HA/polylactic-co-glycolic acid-polyethyleneimine NPs (PP-HA/NPs) were prepared through a modified emulsion solvent evaporation technique. The particle size of PP-HA/NPs with narrow polydispersity was 209.8±10.8nm. Wound healing assay revealed that Qu co-delivery and HA modification elicited synergistic inhibitory effects on cell motility...
March 20, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/28336245/does-the-timing-of-chemotherapy-affect-post-mastectomy-breast-reconstruction-complications
#16
Oriana Cohen, Gretl Lam, Mihye Choi, Nolan Karp, Daniel Ceradini
INTRODUCTION: In this study we evaluated how the timing of chemotherapy for breast cancer affects post-reconstruction complications to determine whether there is an optimal time for breast reconstruction after chemotherapy. PATIENTS AND METHODS: A retrospective review identified 344 breast cancer patients who underwent chemotherapy with mastectomy and autologous/prosthetic reconstruction from 2011 to 2014. A control group of 127 breast cancer patients who underwent mastectomy and autologous/prosthetic reconstruction without chemotherapy was also identified from the same period...
February 17, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28335887/trastuzumab-in-combination-with-weekly-paclitaxel-and-carboplatin-as-neo-adjuvant-treatment-for-her2-positive-breast-cancer-the-train-study
#17
Mette S van Ramshorst, Erik van Werkhoven, Ingrid A M Mandjes, Margaret Schot, Jelle Wesseling, Marie-Jeanne T F D Vrancken Peeters, Jetske M Meerum Terwogt, Monique E M Bos, Hendrika M Oosterkamp, Sjoerd Rodenhuis, Sabine C Linn, Gabe S Sonke
AIM: To determine the efficacy and safety of an anthracycline-free neo-adjuvant regimen consisting of weekly paclitaxel, carboplatin and trastuzumab in HER2-positive breast cancer. PATIENTS AND METHODS: Patients with stage II or III HER2-positive breast cancer received weekly paclitaxel ([P], 70 mg/m(2)), trastuzumab ([T], 2 mg/kg, loading dose 4 mg/kg) and carboplatin ([C], AUC = 3 mg ml(-1) min) for 24 weeks. In weeks 7, 8, 15, 16, 23 and 24, trastuzumab was administered without chemotherapy...
March 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28335647/sorafenib-for-the-treatment-of-breast-cancer
#18
Giuseppe Bronte, Daniele Andreis, Sara Bravaccini, Roberta Maltoni, Lorenzo Cecconetto, Alessio Schirone, Alberto Farolfi, Anna Fedeli, Patrizia Serra, Caterina Donati, Dino Amadori, Andrea Rocca
Breast cancer treatment includes many options depending on the tumor clinicopathological profile, which groups breast cancer into various subtypes. Bevacizumab is currently the only drug capable of targeting angiogenesis in breast cancer. Sorafenib has also been studied in combination with other agents. Areas covered: Pharmacological aspects of sorafenib, including results from preclinical studies on breast cancer cells; findings about clinical efficacy and safety in both single-arm and randomized clinical trials; ongoing trials...
March 24, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28334432/uch-l1-containing-exosomes-mediate-chemotherapeutic-resistance-transfer-in-breast-cancer
#19
Kuan Ning, Teng Wang, Xu Sun, Pengfei Zhang, Yun Chen, Jian Jin, Dong Hua
BACKGROUND: Chemotherapy resistance has become a serious challenge in the treatment of breast cancer. Previous studies showed cells can transfer proteins, including those responsible for drug resistance to adjacent cells via exosomes. METHODS: The switches of drug resistance via exosomes transfer were assessed by CellTiter-Blue Viability assay, flow cytometry, and immunostaining analysis. Relative protein levels of Ubiquitin carboxyl terminal hydrolase-L1 (UCH-L1), P-glycoprotein (P-gp), extracellular-signal regulated protein kinase1/2 (ERK1/2), and phospho-extracellular-signal regulated protein kinase1/2 (p-ERK1/2) were measured by Western blot...
March 23, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28334337/birth-outcomes-among-adolescent-and-young-adult-cancer-survivors
#20
Chelsea Anderson, Stephanie M Engel, Jennifer E Mersereau, Kristin Z Black, William A Wood, Carey K Anders, Hazel B Nichols
Importance: Cancer diagnosis and treatment may adversely affect reproductive outcomes among female cancer survivors. Objective: To compare the birth outcomes of adolescent and young adult cancer survivors (AYA [diagnosed at ages 15-39 years]) with those of women without a cancer diagnosis. Design, Setting, and Participants: The North Carolina Central Cancer Registry (CCR) was used to identify female AYA cancer survivors diagnosed from January 2000 to December 2013; CCR records were linked to statewide birth certificate files from January 2000 to December 2014 to identify postdiagnosis live births to AYA survivors (n = 2598)...
March 23, 2017: JAMA Oncology
keyword
keyword
82103
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"